GlassScriptPhysician profile
William D Keith
NPI 1326188707
$4,100.18
in general payments reported to CMS, 2019-2025
22 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $707 · 2021: $547 · 2022: $604 · 2023: $476 · 2024: $433 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.68 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.51 | 2019-2024 | |
| Merz North America, INC. | $527.26 | 2019-2025 | Xeomin |
| Pfizer INC. | $414.59 | 2019-2024 | |
| Incyte Corporation | $411.10 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $347.68 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $230.18 | 2019-2024 | Winlevi, Odomzo |
| Janssen Biotech, INC. | $227.65 | 2020-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $206.99 | 2019-2021 | |
| Dermavant Sciences, INC. | $206.31 | 2024 | Vtama |
| Lilly USA, LLC | $190.98 | 2020-2025 | Taltz, Ebglyss, Zepbound |
| Genzyme Corporation | $131.27 | 2020-2025 | |
| Ucb, INC. | $121.41 | 2022-2025 | Bimzelx |
| Leo Pharma INC. | $107.98 | 2019-2021 | |
| Amgen INC. | $101.23 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $62.99 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sebela Pharmaceuticals INC. | $60.00 | 2019-2022 | |
| Galderma Laboratories, L.P. | $43.71 | 2020-2025 | Nemluvio |
| Epi Health, LLC | $37.76 | 2019-2020 | |
| Organon LLC | $37.32 | 2025 | Vtama |
| Masimo Corporation | $26.50 | 2022 | |
| Sandoz INC. | $22.76 | 2020 | |
| Glenmark Therapeutics INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.